Glipizide

Specifications

29094-61-9CAS Number

249-427-6EC Number

N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methylpyrazine-2-carboxamideIUPAC Name

C21H27N5O4SChemical Formula

445.5 g/molMolecular Weight

glipizide; 29094-61-9; Glucotrol; Glydiazinamide; Glibenese; Melizide; Minidiab; Minodiab; Dipazide; Glucozide; Glupitel; Glupizide; Napizide; Sucrazide; Mindiab; Ozidia; Glibetin; Glidiab; Glucolip; Minidab; Aldiab; Digrin; Glican; Glipid; Glyde; Gluco-Rite; Glucotrol XL; Glipizida; Glipizidum; K 4024; K-4024; CP-28720; CP 28720; DTXSID0040676; CP 28,720; Glipizide slow release; CP-28,720; X7WDT95N5C; 1-Cyclohexyl-3-((p-(2-(5-methylpyrazinecarboxamido)ethyl)phenyl)sulfonyl)urea; NSC-759120; Glidiazinamide; Glypidizine; Pyrazinecarboxamide, N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-5-methyl-; N-(4-(beta-(5-Methylpyrazine-2-carboxamido)ethyl)benzenesulphonyl)-N'-cyclohexylurea; N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-5-methylpyrazine-2-carboxamide; CHEBI:5384; DTXCID8020676; 1-cyclohexyl-3-[[p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl]sulfonyl]urea; Urea, 1-cyclohexyl-3-((p-(2-(5-methylpyrazinecarboxamido)ethyl)phenyl)sulfonyl)-; 1-cyclohexyl-3-({p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl}sulfonyl)urea; N-{4-[beta-(5-methylpyrazine-2-carboxamido)ethyl]benzenesulphonyl}-N'-cyclohexylurea; Pyrazinecarboxamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl-; K4024; Glipizideer; Glipizideer ER; Glipizide ER; Glipizide XL; Minodiab 5; N-(2-(4-(((cyclohexylcarbamoyl)amino)sulfonyl)phenyl)ethyl)-5-methylpyrazine-2-carboxamide; Minodiab 2.5; RefChem:55253; 249-427-6; Glipizidum [INN-Latin]; Glipizida [INN-Spanish]; C21H27N5O4S; N-(4-(N-(cyclohexylcarbamoyl)sulfamoyl)phenethyl)-5-methylpyrazine-2-carboxamide; MFCD00072159; TK 1320; Glide; CHEMBL1073; MLS000069386; CP 28720;K 4024; N-(2-{4-[(cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-5-methylpyrazine-2-carboxamide; NCGC00015462-07; SMR000058455; CAS-29094-61-9; Glucotrol (TN); Glipizide (USP/INN); SR-01000000010; EINECS 249-427-6; UNII-X7WDT95N5C; BRN 0903495; Glydiazinamide;; Glibenese;; Glipizide CRS; Glipizide, solid; Glucotrol XL;; N-[4-[N-(Cyclohexylcarbamoyl)sulfamoyl]phenethyl]-5-methylpyrazine-2-carboxamide; Glipizide [USAN:USP:INN:BAN]; glipizide/glucotrol; N-[2-[4[[[(Cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methylpyrazinecarboxamide; 1-Cyclohexyl-3-[[p-[2-(5-methylpyrazinecarboxamido); Prestwick_242; Glipizide Impurity U; Glipizide (Standard); KS-1068; Metaglip (Salt/Mix); GLIPIZIDE [INN]; GLIPIZIDE [JAN]; GLIPIZIDE [MI]; Lopac-G-117; GLIPIZIDE [USAN]; Opera_ID_1908; Prestwick0_000131; Prestwick1_000131; Prestwick2_000131; Prestwick3_000131; GLIPIZIDE [VANDF]; G-117; GLIPIZIDE [MART.]; 1-Cyclohexyl-3-{4-[2-(5-methylpyrazine-2-carboxamido)ethyl]phenylsulfonyl}urea; N-[4-(3-Cyclohexylureidosulfonyl)phenethyl]-5-methyl-2-pyrazinecarboxamide; GLIPIZIDE [USP-RS]; GLIPIZIDE [WHO-DD]; N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methyl-pyrazine-2-carboxamide; CBiol_001788; Lopac0_000621; SCHEMBL17094; BSPBio_000202; BSPBio_001349; KBioGR_000069; KBioSS_000069; MLS001148176; BIDD:GT0476; SPBio_002141; BPBio1_000224; GTPL6821; orb1225415; orb1308053; orb3139696; GLIPIZIDE [ORANGE BOOK]; GLIPIZIDE [EP MONOGRAPH]; SCHEMBL29366401; HY-B0254R; KBio2_000069; KBio2_002637; KBio2_005205; KBio3_000137; KBio3_000138; GLIPIZIDE [USP MONOGRAPH]; MSK7193; Bio1_000074; Bio1_000563; Bio1_001052; Bio2_000069; Bio2_000549; GLXC-20257; HMS1361D11; HMS1568K04; HMS1791D11; HMS1989D11; HMS2089C21; HMS2093J09; HMS2095K04; HMS2233N11; HMS3259K12; HMS3261N04; HMS3369L12; HMS3402D11; HMS3655G04; HMS3712K04; HMS5079J16; Pharmakon1600-01505433; METAGLIP COMPONENT GLIPIZIDE; MSK7193-100AM; HY-B0254; PXB42607; MSK7193-1000AM; Tox21_110156; Tox21_301834; Tox21_500621; BDBM50012956; EBC-06101; NSC759120; NSC813218; s1715; STK631952; AKOS005564405; Tox21_110156_1; CCG-204710; DB01067; FG01273; LP00621; NC00564; NSC 759120; NSC-813218; SDCCGSBI-0050603.P003; IDI1_033819; Glipizide 100 microg/mL in Acetonitrile; NCGC00015462-01; NCGC00015462-02; NCGC00015462-03; NCGC00015462-04; NCGC00015462-05; NCGC00015462-06; NCGC00015462-08; NCGC00015462-09; NCGC00015462-10; NCGC00015462-11; NCGC00015462-12; NCGC00015462-14; NCGC00015462-15; NCGC00015462-23; NCGC00016802-01; NCGC00023748-03; NCGC00023748-04; NCGC00023748-05; NCGC00023748-06; NCGC00023748-07; NCGC00255522-01; NCGC00261306-01; 2-Pyrazinecarboxamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl-; AC-15789; SY009252; SBI-0050603.P002; EU-0100621; G0369; G4634; NS00009815; ST50826363; SW196549-3; D00335; F857701; Q3108899; SR-01000000010-2; SR-01000000010-5; BRD-K12219985-001-04-8; BRD-K12219985-001-15-4; BRD-K12219985-001-25-3; BRD-K12219985-001-26-1; Glipizide Solution in Acetonitrile/Methanol, 100ug/mL; Glipizide Solution in Acetonitrile/Methanol, 1000ug/mL; Z1575081877; Glipizide, European Pharmacopoeia (EP) Reference Standard; Glipizide, United States Pharmacopeia (USP) Reference Standard; Glipizide, Pharmaceutical Secondary Standard; Certified Reference Material; 1-cyclohexyl-3-(4-(2-(2-methylpyrazine-5-carboxamido)ethyl)phenylsulfonyl)urea; 1-Cyclohexyl-3-{{p=[2-[5-methylpyrazine-carboxamido)-ethyl]phenyl}sulphonyl}urea; N-(4-(.beta.-(5-Methylpyrazine-2-carboxamido)ethyl)benzenesulphonyl)-N'-cyclohexylurea; 172964-66-8; N-(2-[4-(([(Cyclohexylamino)carbonyl]amino)sulfonyl)phenyl]ethyl)-5-methyl-2-pyrazinecarboxamide; N-[2-(4-{[(cyclohexylamino)carbonylamino]sulfonyl}phenyl)ethyl](5-methylpyrazi n-2-yl)carboxamideSynonyms